Management of Myocarditis-Related Cardiomyopathy in Adults

Circulation Research

Volumn 124, Issue 11, 2019, Pages 1568-1583

  Tschöpe, Carsten ^a,b   Cooper, Leslie T ^c   Torre Amione, Guillermo ^d,e   Van Linthout, Sophie ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c MAYO CLINIC   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

^e ESCUELA DE MEDICINA Y CIENCIAS DE LA SALUD   (Mexico)

Author keywords

biopsy; cardiomyopathies; heart; inflammation; myocarditis

Indexed keywords

ACICLOVIR; ANAKINRA; AZATHIOPRINE; BETA INTERFERON; CANAKINUMAB; COLCHICINE; GANCICLOVIR; HIGH MOBILITY GROUP B1 PROTEIN INHIBITOR; IMMUNOGLOBULIN; INTERLEUKIN 2; NANOCARRIER; PREDNISONE; PROTEIN INHIBITOR; RITUXIMAB; S100A9 INHIBITOR; STEROID; TELBIVUDINE; UNCLASSIFIED DRUG; VALACICLOVIR;

ACUTE HEART FAILURE; ADENOVIRUS INFECTION; ANTIVIRAL THERAPY; ARTICLE; AUTOIMMUNE DISEASE; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE MANAGEMENT; DISEASE SEVERITY; ENTEROVIRUS INFECTION; ERYTHEMA INFECTIOSUM; GENOME ANALYSIS; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HERPES VIRUS INFECTION; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STROMA CELL; MORTALITY RISK; MYOCARDITIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TRANSLATIONAL RESEARCH; VIRUS GENOME; VIRUS INFECTION; ANIMAL; CONVALESCENCE; DISEASE EXACERBATION; PATHOPHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; CARDIOMYOPATHIES; DISEASE PROGRESSION; HEART FAILURE; HUMANS; MYOCARDITIS; RECOVERY OF FUNCTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 85066843746     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.118.313578     Document Type: Article

References (215)

1. Cooper LT Jr. Myocarditis. N Engl J Med. 2009;360:1526-1538. doi: 10.1056/NEJMra0800028
2. Caforio AL, Pankuweit S, Arbustini E, et al; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636-2648, 2648a. doi: 10.1093/eurheartj/eht210
3. Ammirati E, Cipriani M, Moro C, et al; Registro Lombardo delle Miocarditi. Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis. Circulation. 2018;138:1088-1099. doi: 10.1161/CIRCULATIONAHA.118.035319
4. Trachtenberg BH, Hare JM. Inflammatory cardiomyopathic syndromes. Circ Res. 2017;121:803-818. doi: 10.1161/CIRCRESAHA.117.310221
5. Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss HP. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation. 2005;111:887-893. doi: 10.1161/01.CIR.0000155616.07901.35
6. Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579-1589. doi: 10.1016/S1470-2045(18)30608-9
7. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391:933. doi: 10.1016/S0140-6736(18)30533-6
8. Remes J, Helin M, Vaino P, Rautio P. Clinical outcome and left ventricular function 23 years after acute coxsackie virus myopericarditis. Eur Heart J. 1990;11:182-188.
9. Van Linthout S, Tschöpe C, Schultheiss HP. Lack in treatment options for virus-induced inflammatory cardiomyopathy: can iPS-derived cardiomyocytes close the gap? Circ Res. 2014;115:540-541. doi: 10.1161/CIRCRESAHA.114.304951
10. McCarthy RE III, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, Baughman KL. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med. 2000;342:690-695. doi: 10.1056/NEJM200003093421003
11. Bozkurt B, Colvin M, Cook J, et al; American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Quality of Care and Outcomes Research. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific Statement From the American Heart Association. Circulation. 2016;134:e579-e646. doi: 10.1161/CIR.0000000000000455
12. Heymans S, Eriksson U, Lehtonen J, Cooper LT Jr. The quest for new approaches in myocarditis and inflammatory cardiomyopathy. J Am Coll Cardiol. 2016;68:2348-2364. doi: 10.1016/j.jacc.2016.09.937
13. Maisch B, Hufnagel G, Kölsch S, Funck R, Richter A, Rupp H, Herzum M, Pankuweit S. Treatment of inflammatory dilated cardiomyopathy and (peri)myocarditis with immunosuppression and i.v. immunoglobulins. Herz. 2004;29:624-636. doi: 10.1007/s00059-004-2628-7
14. Dominguez F, Kuhl U, Pieske B, Garcia-Pavia P, Tschöpe C. Update on myocarditis and inflammatory cardiomyopathy: reemergence of endomyocardial biopsy. Rev Esp Cardiol (Engl Ed). 2016;69:178-187.
15. Caforio ALP, Malipiero G, Marcolongo R, Iliceto S. Myocarditis: a clinical overview. Curr Cardiol Rep. 2017;19:63. doi: 10.1007/s11886-017-0870-x
16. Ammirati E, Veronese G, Cipriani M, Moroni F, Garascia A, Brambatti M, Adler ED, Frigerio M. Acute and fulminant myocarditis: a pragmatic clinical approach to diagnosis and treatment. Curr Cardiol Rep. 2018;20:114.
17. Bock CT, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med. 2010;362:1248-1249. doi: 10.1056/NEJMc0911362
18. Ferreira MV, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, Kindermann I, Gutberlet M, Cooper LT, Liu P, Friedrich MG. Cardiovascular magnetic resonance in nonischemic myocardial inflammation. JACC Sci Expert Panel. 2018;72:3158-3176.
19. Ammirati E, Sormani P, Moroni F, Camici PG, Pedrotti P. Changes of late gadolinium enhancement extension compared with native T1 mapping early after acute myocarditis. Int J Cardiol. 2018;257:227. doi: 10.1016/j.ijcard.2017.12.056
20. Francis R, Lewis C. Myocardial biopsy: techniques and indications. Heart. 2018;104:950-958. doi: 10.1136/heartjnl-2017-311382
21. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R; American Heart Association; American College of Cardiology; European Society of Cardiology. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116:2216-2233. doi: 10.1161/CIRCULATIONAHA.107.186093
22. Lurz P, Eitel I, Adam J, Steiner J, Grothoff M, Desch S, Fuernau G, de Waha S, Sareban M, Luecke C, Klingel K, Kandolf R, Schuler G, Gutberlet M, Thiele H. Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. JACC Cardiovasc Imaging. 2012;5:513-524. doi: 10.1016/j.jcmg.2011.11.022
23. Lurz P, Luecke C, Eitel I, Föhrenbach F, Frank C, Grothoff M, de Waha S, Rommel KP, Lurz JA, Klingel K, Kandolf R, Schuler G, Thiele H, Gutberlet M. Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: the myoracer-trial. J Am Coll Cardiol. 2016;67:1800-1811. doi: 10.1016/j.jacc.2016.02.013
24. Shanbhag SM, Greve AM, Aspelund T, Schelbert EB, Cao JJ, Danielsen R, Torgeirsson G, Sigurdsson S, Eiríksdóttir G, Harris TB, Launer LJ, Gudnason V, Arai AE. Prevalence and prognosis of ischaemic and non-ischaemic myocardial fibrosis in older adults. Eur Heart J. 2019;40:529-538. doi: 10.1093/eurheartj/ehy713
25. Ponikowski P, Voors AA, Anker SD, et al; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891-975. doi: 10.1002/ejhf.592
26. Torre-Amione G, Anker SD, Bourge RC, et al; Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy Investigators. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet. 2008;371:228-236. doi: 10.1016/S0140-6736(08)60134-8
27. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009;30:1995-2002. doi: 10.1093/eurheartj/ehp249
28. Escher F, Kühl U, Lassner D, Poller W, Westermann D, Pieske B, Tschöpe C, Schultheiss HP. Long-term outcome of patients with virusnegative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy. Clin Res Cardiol. 2016;105:1011-1020. doi: 10.1007/s00392-016-1011-z
29. Merken J, Hazebroek M, Van Paassen P, Verdonschot J, Van Empel V, Knackstedt C, Abdul Hamid M, Seiler M, Kolb J, Hoermann P, Ensinger C, Brunner-La Rocca HP, Poelzl G, Heymans S. Immunosuppressive therapy improves both short-and long-term prognosis in patients with virusnegative nonfulminant inflammatory cardiomyopathy. Circ Heart Fail. 2018;11:e004228. doi: 10.1161/CIRCHEARTFAILURE.117.004228
30. Kindermann I, Kindermann M, Kandolf R, Klingel K, Bültmann B, Müller T, Lindinger A, Böhm M. Predictors of outcome in patients with suspected myocarditis. Circulation. 2008;118:639-648. doi: 10.1161/CIRCULATIONAHA.108.769489
31. Baughman KL. Diagnosis of myocarditis: death of Dallas criteria. Circulation. 2006;113:593-595. doi: 10.1161/CIRCULATIONAHA.105.589663
32. Chow LH, Radio SJ, Sears TD, McManus BM. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol. 1989;14:915-920.
33. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis-natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med. 1997;336:1860-1866. doi: 10.1056/NEJM199706263362603
34. Kandolin R, Lehtonen J, Salmenkivi K, Räisänen-Sokolowski A, Lommi J, Kupari M. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail. 2013;6:15-22. doi: 10.1161/CIRCHEARTFAILURE.112.969261
35. Leone O, Veinot JP, Angelini A, et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol. 2012;21:245-274. doi: 10.1016/j.carpath.2011.10.001
36. Bennett MK, Gilotra NA, Harrington C, Rao S, Dunn JM, Freitag TB, Halushka MK, Russell SD. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009. Circ Heart Fail. 2013;6:676-684. doi: 10.1161/CIRCHEARTFAILURE.112.000087
37. Unterberg-Buchwald C, Ritter CO, Reupke V, Wilke RN, Stadelmann C, Steinmetz M, Schuster A, Hasenfus G, Lotz J, Uecker M. Targeted endomyocardial biopsy guided by real-time cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2017;19:45. doi: 10.1186/s12968-017-0357-3
38. Casella M, Pizzamiglio F, Dello Russo A, et al. Feasibility of combined unipolar and bipolar voltage maps to improve sensitivity of endomyocardial biopsy. Circ Arrhythm Electrophysiol. 2015;8:625-632. doi: 10.1161/CIRCEP.114.002216
39. Liang JJ, Hebl VB, DeSimone CV, Madhavan M, Nanda S, Kapa S, Maleszewski JJ, Edwards WD, Reeder G, Cooper LT, Asirvatham SJ. Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis. JACC Heart Fail. 2014;2:466-473. doi: 10.1016/j.jchf.2014.03.015
40. Konecny T, Noseworthy PA, Kapa S, Cooper LT, Mulpuru SK, Sandhu GS, Asirvatham S. Endomyocardial biopsy-integrating electrode at the bioptome tip. Ther Adv Cardiovasc Dis. 2015;9:66-69. doi: 10.1177/1753944715574660
41. Vaidya VR, Abudan AA, Vasudevan K, Shantha G, Cooper LT, Kapa S, Noseworthy PA, Cha YM, Asirvatham SJ, Deshmukh AJ. The efficacy and safety of electroanatomic mapping-guided endomyocardial biopsy: a systematic review. J Interv Card Electrophysiol. 2018;53:63-71. doi: 10.1007/s10840-018-0410-7
42. Omote K, Naya M, Koyanagawa K, Aikawa T, Manabe O, Nagai T, Kamiya K, Kato Y, Komoriyama H, Kuzume M, Tamaki N, Anzai T. (18) F-FDG uptake of the right ventricle is an important predictor of histopathologic diagnosis by endomyocardial biopsy in patients with cardiac sarcoidosis [published online January 4, 2019]. J Nucl Cardiol. doi: 10.1007/s12350-018-01541-7
43. Gannon MP, Schaub E, Grines CL, Saba SG. State of the art: Evaluation and prognostication of myocarditis using cardiac MRI. J Magn Reson Imaging. 2019.
44. Tschöpe C, Kherad B, Schultheiss HP. How to perform an endomyocardial biopsy? Turk Kardiyol Dern Ars. 2015;43:572-575. doi: 10.5543/tkda.2015.91298
45. Holzmann M, Nicko A, Kühl U, Noutsias M, Poller W, Hoffmann W, Morguet A, Witzenbichler B, Tschöpe C, Schultheiss HP, Pauschinger M. Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. Circulation. 2008;118:1722-1728. doi: 10.1161/CIRCULATIONAHA.107.743427
46. McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, Janosko K, Tokarczyk T, Kessler P, Mann DL, Feldman AM. Controlled trial of intravenous immune globulin in recentonset dilated cardiomyopathy. Circulation. 2001;103:2254-2259.
47. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T, Zembala M, Polonski L, Rozek MM, Wodniecki J. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001;104:39-45.
48. Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-e239. doi: 10.1016/j.jacc.2013.05.019
49. Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37:1850-1858. doi: 10.1093/eurheartj/ehv727
50. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines-CPG; Document Reviewers. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14:1385-1413. doi: 10.1093/europace/eus305
51. Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Estes NAM III, Cooper LT Jr, Link MS, Maron MS. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2015;66:2362-2371. doi: 10.1016/j.jacc.2015.09.035
52. Ammirati E, Cipriani M, Lilliu M, et al. Survival and left ventricular function changes in fulminant versus nonfulminant acute myocarditis. Circulation. 2017;136:529-545. doi: 10.1161/CIRCULATIONAHA.117.026386
53. Ekström K, Lehtonen J, Kandolin R, Räisänen-Sokolowski A, Salmenkivi K, Kupari M. Long-term outcome and its predictors in giant cell myocarditis. Eur J Heart Fail. 2016;18:1452-1458. doi: 10.1002/ejhf.606
54. Maleszewski JJ, Orellana VM, Hodge DO, Kuhl U, Schultheiss HP, Cooper LT. Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J Cardiol. 2015;115:1733-1738. doi: 10.1016/j.amjcard.2015.03.023
55. Tai PC, Ackerman SJ, Spry CJ, Dunnette S, Olsen EG, Gleich GJ. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet. 1987;1:643-647.
56. Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG, Ammirati E. Eosinophilic myocarditis: characteristics, treatment, and outcomes. J Am Coll Cardiol. 2017;70:2363-2375.
57. Bleeker JS, Syed FF, Cooper LT, Weiler CR, Tefferi A, Pardanani A. Treatment-refractory idiopathic hypereosinophilic syndrome: pitfalls and progress with use of novel drugs. Am J Hematol. 2012;87:703-706. doi: 10.1002/ajh.23120
58. Latham RD, Mulrow JP, Virmani R, Robinowitz M, Moody JM. Recently diagnosed idiopathic dilated cardiomyopathy: incidence of myocarditis and efficacy of prednisone therapy. Am Heart J. 1989;117:876-882.
59. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE. A clinical trial of immunosuppressive therapy for myocarditis. The myocarditis treatment trial investigators. N Engl J Med. 1995;333:269-275. doi: 10.1056/NEJM199508033330501
60. Boehmer JP, Starling RC, Cooper LT, Torre-Amione G, Wittstein I, Dec GW, Markham DW, Zucker MJ, Gorcsan J III, McTiernan C, Kip K, McNamara DM; IMAC Investigators. Left ventricular assist device support and myocardial recovery in recent onset cardiomyopathy. J Card Fail. 2012;18:755-761. doi: 10.1016/j.cardfail.2012.08.001
61. Rihal CS, Naidu SS, Givertz MM, Szeto WY, Burke JA, Kapur NK, Kern M, Garratt KN, Goldstein JA, Dimas V, Tu T; Society for Cardiovascular Angiography and Interventions (SCAI); Heart Failure Society of America (HFSA); Society of Thoracic Surgeons (STS); American Heart Association (AHA), and American College of Cardiology (ACC). 2015 SCAI/ACC/HFSA/sts clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care: Endorsed by the American Heart Assocation, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'intervention. J Am Coll Cardiol. 2015;65:e7-e26. doi: 10.1016/j.jacc.2015.03.036
62. Hsu KH, Chi NH, Yu HY, Wang CH, Huang SC, Wang SS, Ko WJ, Chen YS. Extracorporeal membranous oxygenation support for acute fulminant myocarditis: analysis of a single center's experience. Eur J Cardiothorac Surg. 2011;40:682-688. doi: 10.1016/j.ejcts.2010.12.050
63. Diddle JW, Almodovar MC, Rajagopal SK, Rycus PT, Thiagarajan RR. Extracorporeal membrane oxygenation for the support of adults with acute myocarditis. Crit Care Med. 2015;43:1016-1025. doi: 10.1097/CCM.0000000000000920
64. Lorusso R, Centofanti P, Gelsomino S, et al; GIROC Investigators. Venoarterial extracorporeal membrane oxygenation for acute fulminant myocarditis in adult patients: a 5-year multi-institutional experience. Ann Thorac Surg. 2016;101:919-926. doi: 10.1016/j.athoracsur.2015.08.014
65. den Uil CA, Akin S, Jewbali LS, Dos Reis Miranda D, Brugts JJ, Constantinescu AA, Kappetein AP, Caliskan K. Short-term mechanical circulatory support as a bridge to durable left ventricular assist device implantation in refractory cardiogenic shock: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2017;52:14-25. doi: 10.1093/ejcts/ezx088
66. Asaumi Y, Yasuda S, Morii I, Kakuchi H, Otsuka Y, Kawamura A, Sasako Y, Nakatani T, Nonogi H, Miyazaki S. Favourable clinical outcome in patients with cardiogenic shock due to fulminant myocarditis supported by percutaneous extracorporeal membrane oxygenation. Eur Heart J. 2005;26:2185-2192. doi: 10.1093/eurheartj/ehi411
67. Tschöpe C, Van Linthout S, Klein O, Mairinger T, Krackhardt F, Potapov E, Schmidt G, Burkhoff D, Pieske B, Spillmann F. Mechanical unloading by fulminant myocarditis: LV-IMPELLA, ECMELLA, BIPELLA and PROPELLA concepts[published online August 6, 2018]. J Cardiovasc Transl Res. doi: 10.1007/s12265-018-9820-2
68. Chen C, Li R, Ross RS, Manso AM. Integrins and integrin-related proteins in cardiac fibrosis. J Mol Cell Cardiol. 2016;93:162-174. doi: 10.1016/j.yjmcc.2015.11.010
69. Lindner D, Zietsch C, Tank J, Sossalla S, Fluschnik N, Hinrichs S, Maier L, Poller W, Blankenberg S, Schultheiss HP, Tschöpe C, Westermann D. Cardiac fibroblasts support cardiac inflammation in heart failure. Basic Res Cardiol. 2014;109:428. doi: 10.1007/s00395-014-0428-7
70. Van Linthout S, Tschöpe C. Inflammation-cause or consequence of heart failure or both? Curr Heart Fail Rep. 2017;14:251-265. doi: 10.1007/s11897-017-0337-9
71. Andrade JG, Al-Saloos H, Jeewa A, Sandor GG, Cheung A. Facilitated cardiac recovery in fulminant myocarditis: pediatric use of the Impella LP 5.0 pump. J Heart Lung Transplant. 2010;29:96-97. doi: 10.1016/j.healun.2009.06.020
72. Suradi H, Breall JA. Successful use of the Impella device in giant cell myocarditis as a bridge to permanent left ventricular mechanical support. Tex Heart Inst J. 2011;38:437-440.
73. Fox H, Farr M, Horstkotte D, Flottmann C. Fulminant myocarditis managed by extracorporeal life support (Impella® CP): a rare case. Case Rep Cardiol. 2017;2017:9231959. doi: 10.1155/2017/9231959
74. Narain S, Paparcuri G, Fuhrman TM, Silverman RB, Peruzzi WT. Novel combination of impella and extra corporeal membrane oxygenation as a bridge to full recovery in fulminant myocarditis. Case Rep Crit Care. 2012;2012:459296. doi: 10.1155/2012/459296
75. Chaparro SV, Badheka A, Marzouka GR, Tanawuttiwat T, Ahmed F, Sacher V, Pham SM. Combined use of Impella left ventricular assist device and extracorporeal membrane oxygenation as a bridge to recovery in fulminant myocarditis. ASAIO J. 2012;58:285-287. doi: 10.1097/MAT.0b013e31824b1f70
76. Beurtheret S, Mordant P, Pavie A, Leprince P. Impella and extracorporeal membrane oxygenation: a demanding combination. ASAIO J. 2012;58:291-293. doi: 10.1097/MAT.0b013e31824c38ef
77. Pappalardo F, Schulte C, Pieri M, et al. Concomitant implantation of Impella® on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail. 2017;19:404-412. doi: 10.1002/ejhf.668
78. Pappalardo F, Scandroglio AM, Latib A. Full percutaneous biventricular support with two Impella pumps: the Bi-Pella approach. ESC Heart Fail. 2018;5:368-371. doi: 10.1002/ehf2.12274
79. Spillmann F, Van Linthout S, Schmidt G, Klein O, Hamdani N, Mairinger T, Krackhardt F, Maroski B, Schlabs T, Soltani S, Anker S, Potapov EV, Burkhoff D, Pieske B, Tschope C. Mode-of-action of the PROPELLA concept in fulminant myocarditis. Eur Heart J. 2019;ehz124.
80. Felix SB, Staudt A, Dörffel WV, Stangl V, Merkel K, Pohl M, Döcke WD, Morgera S, Neumayer HH, Wernecke KD, Wallukat G, Stangl K, Baumann G. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol. 2000;35:1590-1598.
81. Trimpert C, Herda LR, Eckerle LG, Pohle S, Müller C, Landsberger M, Felix SB, Staudt A. Immunoadsorption in dilated cardiomyopathy: long-term reduction of cardiodepressant antibodies. Eur J Clin Invest. 2010;40:685-691. doi: 10.1111/j.1365-2362.2010.02314.x
82. Dandel M, Wallukat G, Englert A, Lehmkuhl HB, Knosalla C, Hetzer R. Long-term benefits of immunoadsorption in β(1)-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy. Eur J Heart Fail. 2012;14:1374-1388. doi: 10.1093/eurjhf/hfs123
83. Yu M, Wen S, Wang M, Liang W, Li HH, Long Q, Guo HP, Liao YH, Yuan J. TNF-α-secreting B cells contribute to myocardial fibrosis in dilated cardiomyopathy. J Clin Immunol. 2013;33:1002-1008. doi: 10.1007/s10875-013-9889-y
84. Weber MS, Prod'homme T, Patarroyo JC, Molnarfi N, Karnezis T, Lehmann-Horn K, Danilenko DM, Eastham-Anderson J, Slavin AJ, Linington C, Bernard CC, Martin F, Zamvil SS. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol. 2010;68:369-383. doi: 10.1002/ana.22081
85. Abbasi AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 8th ed. Philadelphia, PA: ELSEVIER Saunders; 2015.
86. Cordero-Reyes AM, Youker KA, Torre-Amione G. The role of B-cells in heart failure. Methodist Debakey Cardiovasc J. 2013;9:15-19.
87. Zouggari Y, Ait-Oufella H, Bonnin P, et al. B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med. 2013;19:1273-1280. doi: 10.1038/nm.3284
88. Brihaye B, Aouba A, Pagnoux C, Vignaux O, Le Hello C, Guillevin L. Rituximab reversed cardiac involvement of Wegener's granulomatosis: magnetic resonance imaging assessment. Presse Med. 2008;37(3 pt 1):412-415. doi: 10.1016/j.lpm.2007.08.019
89. Matsumoto Y, Park IK, Kohyama K. B-cell epitope spreading is a critical step for the switch from C-protein-induced myocarditis to dilated cardiomyopathy. Am J Pathol. 2007;170:43-51. doi: 10.2353/ajpath.2007.060544
90. Nikolaidis LA. When cancer and heart failure cross paths: a case report of severe cardiorenal compromise associated with the anti-CD20 monoclonal antibody rituximab in a patient with dilated cardiomyopathy. Congest Heart Fail. 2001;7:223-227.
91. Touma Z, Arayssi T, Kibbi L, Masri AF. Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint Bone Spine. 2008;75:334-337. doi: 10.1016/j.jbspin.2007.05.011
92. Wang CR, Tsai YS, Li WT. Lupus myocarditis receiving the rituximab therapy-A monocentric retrospective study. Clin Rheumatol. 2018;37:1701-1707. doi: 10.1007/s10067-017-3971-4
93. Toscano G, Tartaro P, Fedrigo M, Angelini A, Marcolongo R. Rituximab in recurrent idiopathic giant cell myocarditis after heart transplantation: a potential therapeutic approach. Transpl Int. 2014;27:e38-e42. doi: 10.1111/tri.12270
94. Ravichandran AK, Schilling JD, Novak E, Pfeifer J, Ewald GA, Joseph SM. Rituximab is associated with improved survival in cardiac allograft patients with antibody-mediated rejection: a single center review. Clin Transplant. 2013;27:961-967. doi: 10.1111/ctr.12277
95. Schultheiss HP, Piper C, Sowade O, Waagstein F, Kapp JF, Wegscheider K, Groetzbach G, Pauschinger M, Escher F, Arbustini E, Siedentop H, Kuehl U. Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol. 2016;105:763-773. doi: 10.1007/s00392-016-0986-9
96. Kühl U, Lassner D, von Schlippenbach J, Poller W, Schultheiss HP. Interferon-Beta improves survival in enterovirus-associated cardiomyopathy. J Am Coll Cardiol. 2012;60:1295-1296. doi: 10.1016/j.jacc. 2012.06.026
97. Schmidt-Lucke C, Spillmann F, Bock T, Kühl U, Van Linthout S, Schultheiss HP, Tschöpe C. Interferon beta modulates endothelial damage in patients with cardiac persistence of human parvovirus b19 infection. J Infect Dis. 2010;201:936-945. doi: 10.1086/650700
98. Escher F, Kühl U, Gross U, Westermann D, Poller W, Tschöpe C, Lassner D, Schultheiss HP. Aggravation of left ventricular dysfunction in patients with biopsy-proven cardiac human herpesvirus A and B infection. J Clin Virol. 2015;63:1-5. doi: 10.1016/j.jcv.2014.11.026
99. Krueger GR, Ablashi DV. Human herpesvirus-6: a short review of its biological behavior. Intervirology. 2003;46:257-269. doi: 10.1159/000073205
100. Kühl U, Lassner D, Wallaschek N, Gross UM, Krueger GR, Seeberg B, Kaufer BB, Escher F, Poller W, Schultheiss HP. Chromosomally integrated human herpesvirus 6 in heart failure: prevalence and treatment. Eur J Heart Fail. 2015;17:9-19. doi: 10.1002/ejhf.194
101. Van Linthout S, Tschöpe C. Viral myocarditis: a prime example for endomyocardial biopsy-guided diagnosis and therapy. Curr Opin Cardiol. 2018;33:325-333. doi: 10.1097/HCO.0000000000000515
102. Bültmann BD, Sotlar K, Klingel K. Parvovirus B19. N Engl J Med. 2004;350:2006-2007; author reply 2006. doi: 10.1056/NEJM200405063501920
103. Tschöpe C, Bock CT, Kasner M, Noutsias M, Westermann D, Schwimmbeck PL, Pauschinger M, Poller WC, Kühl U, Kandolf R, Schultheiss HP. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation. 2005;111:879-886. doi: 10.1161/01.CIR.0000155615.68924.B3
104. Bachelier K, Biehl S, Schwarz V, Kindermann I, Kandolf R, Sauter M, Ukena C, Yilmaz A, Sliwa K, Bock CT, Klingel K, Böhm M. Parvovirus B19-induced vascular damage in the heart is associated with elevated circulating endothelial microparticles. PLoS One. 2017;12:e0176311. doi: 10.1371/journal.pone.0176311
105. Duechting A, Tschöpe C, Kaiser H, Lamkemeyer T, Tanaka N, Aberle S, Lang F, Torresi J, Kandolf R, Bock CT. Human parvovirus B19 NS1 protein modulates inflammatory signaling by activation of STAT3/PIAS3 in human endothelial cells. J Virol. 2008;82:7942-7952. doi: 10.1128/JVI.00891-08
106. Schmidt-Lucke C, Zobel T, Schrepfer S, et al. Impaired endothelial regeneration through human parvovirus b19-infected circulating angiogenic cells in patients with cardiomyopathy. J Infect Dis. 2015;212:1070-1081. doi: 10.1093/infdis/jiv178
107. Dettmeyer R, Kandolf R, Baasner A, Banaschak S, Eis-Hübinger AM, Madea B. Fatal parvovirus B19 myocarditis in an 8-year-old boy. J Forensic Sci. 2003;48:183-186.
108. Schenk T, Enders M, Pollak S, Hahn R, Huzly D. High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy. J Clin Microbiol. 2009;47:106-110. doi: 10.1128/JCM.01672-08
109. Lotze U, Egerer R, Glück B, Zell R, Sigusch H, Erhardt C, Heim A, Kandolf R, Bock T, Wutzler P, Figulla HR. Low level myocardial parvovirus B19 persistence is a frequent finding in patients with heart disease but unrelated to ongoing myocardial injury. J Med Virol. 2010;82:1449-1457. doi: 10.1002/jmv.21821
110. Norja P, Hokynar K, Aaltonen LM, Chen R, et al. Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proc Natl Acad Sci USA. 2006;103:7450-7453. doi: 10.1073/pnas.0602259103
111. Bock CT, Düchting A, Utta F, Brunner E, Sy BT, Klingel K, Lang F, Gawaz M, Felix SB, Kandolf R. Molecular phenotypes of human parvovirus B19 in patients with myocarditis. World J Cardiol. 2014;6:183-195. doi: 10.4330/wjc.v6.i4.183
112. Dennert R, van Paassen P, Wolffs P, Bruggeman C, Velthuis S, Felix S, van Suylen RJ, Crijns HJ, Cohen Tervaert JW, Heymans S. Differences in virus prevalence and load in the hearts of patients with idiopathic dilated cardiomyopathy with and without immune-mediated inflammatory diseases. Clin Vaccine Immunol. 2012;19:1182-1187. doi: 10.1128/CVI.00281-12
113. Kuhl U, Lassner D, Dorner A, Rohde M, Escher F, Seeberg B, Hertel E, Tschope C, Skurk C, Gross UM, Schultheiss HP, Poller W. A distinct subgroup of cardiomyopathy patients characterized by transcriptionally active cardiotropic erythrovirus and altered cardiac gene expression. Basic Res Cardiol. 2013;108:372. doi: 10.1007/s00395-013-0372-y
114. Verdonschot J, Hazebroek M, Merken J, Debing Y, Dennert R, Brunner-La Rocca HP, Heymans S. Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature. Eur J Heart Fail. 2016;18:1430-1441. doi: 10.1002/ejhf.665
115. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science. 2008;320:373-376. doi: 10.1126/science.1154315
116. Dennert R, Velthuis S, Schalla S, Eurlings L, van Suylen RJ, van Paassen P, Tervaert JW, Wolffs P, Goossens VJ, Bruggeman C, Waltenberger J, Crijns HJ, Heymans S. Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. Antivir Ther. 2010;15:193-201. doi: 10.3851/IMP1516
117. Keam SJ. Telbivudine. Drugs. 2007;67:1917-1929. doi: 10.2165/00003495-200767130-00011
118. Meng N, Gao X, Yan W, Wang M, Liu P, Lu XD, Zhang SJ, Lu YQ, Tang WX. Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses. J Huazhong Univ Sci Technolog Med Sci. 2015;35:230-234. doi: 10.1007/s11596-015-1416-3
119. Pan X, Yao W, Fu J, Liu M, Li L, Gao X. Telbivudine improves the function of myeloid dendritic cells in patients with chronic hepatitis B. Acta Virol. 2012;56:31-38.
120. Li J, Jia M, Liu Y, She W, Li L, Wang J, Jiang W. Telbivudine therapy may shape CD4(+) T-cell response to prevent liver fibrosis in patients with chronic hepatitis B. Liver Int. 2015;35:834-845. doi: 10.1111/liv.12589
121. Chen Y, Li X, Ye B, Yang X, Wu W, Chen B, Pan X, Cao H, Li L. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Antiviral Res. 2011;91:23-31. doi: 10.1016/j.antiviral.2011.04.008
122. Van Linthout S, Elsanhoury A, Klein O, Sosnowski M, Miteva K, Lassner D, Abou-El-Enein M, Pieske B, Kühl U, Tschöpe C. Telbivudine in chronic lymphocytic myocarditis and human parvovirus B19 transcriptional activity. ESC Heart Fail. 2018;5:818-829. doi: 10.1002/ehf2.12341
123. Kühl U, Lassner D, Pauschinger M, Gross UM, Seeberg B, Noutsias M, Poller W, Schultheiss HP. Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy. J Med Virol. 2008;80:1243-1251. doi: 10.1002/jmv.21187
124. Ozawa K, Kurtzman G, Young N. Productive infection by B19 parvovirus of human erythroid bone marrow cells in vitro. Blood. 1987;70:384-391.
125. Tschöpe C, Van Linthout S, Pieske B, Kühl U. Immunosuppression in lymphocytic myocarditis with parvovirus B19 presence. Eur J Heart Fail. 2018;20:609.
126. Abbate A, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013;111:1394-1400. doi: 10.1016/j.amjcard.2013.01.287
127. Van Tassell BW, Abouzaki NA, Oddi Erdle C, et al. Interleukin-1 blockade in acute decompensated heart failure: a randomized, doubleblinded, placebo-controlled pilot study. J Cardiovasc Pharmacol. 2016;67:544-551. doi: 10.1097/FJC.0000000000000378
128. Van Tassell BW, Arena R, Biondi-Zoccai G, Canada JM, Oddi C, Abouzaki NA, Jahangiri A, Falcao RA, Kontos MC, Shah KB, Voelkel NF, Dinarello CA, Abbate A. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol. 2014;113:321-327. doi: 10.1016/j.amjcard.2013.08.047
129. Cavalli G, Foppoli M, Cabrini L, Dinarello CA, Tresoldi M, Dagna L. Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure. Front Immunol. 2017;8:131. doi: 10.3389/fimmu.2017.00131
130. Cavalli G, Pappalardo F, Mangieri A, Dinarello CA, Dagna L, Tresoldi M. Treating Life-Threatening Myocarditis by Blocking Interleukin-1. Crit Care Med. 2016;44:e751-e754. doi: 10.1097/CCM.0000000000001654
131. Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-1131. doi: 10.1056/NEJMoa1707914
132. Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F, Moratti M, Gaschino G, Giammaria M, Ghisio A, Belli R, Trinchero R. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112:2012-2016. doi: 10.1161/CIRCULATIONAHA.105.542738
133. Brucato A, Maestroni S, Cumetti D, Thiella G, Alari G, Brambilla G, Imazio M, Doria A, Palmieri G, Adler Y. Recurrent pericarditis: infectious or autoimmune? Autoimmun Rev. 2008;8:44-47. doi: 10.1016/j.autrev.2008.07.024
134. Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, Trinchero R, Spodick DH, Adler Y; CORP (COlchicine for Recurrent Pericarditis) Investigators. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155:409-414. doi: 10.7326/0003-4819-155-7-201110040-00359
135. Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F, Demarie D, Forno D, Ferro S, Maestroni S, Belli R, Trinchero R, Spodick DH, Adler Y; ICAP Investigators. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369:1522-1528. doi: 10.1056/NEJMoa1208536
136. Deftereos S, Giannopoulos G, Papoutsidakis N, Panagopoulou V, Kossyvakis C, Raisakis K, Cleman MW, Stefanadis C. Colchicine and the heart: pushing the envelope. J Am Coll Cardiol. 2013;62:1817-1825. doi: 10.1016/j.jacc.2013.08.726
137. Imazio M, Trinchero R, Brucato A, et al; COPPS Investigators. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J. 2010;31:2749-2754. doi: 10.1093/eurheartj/ehq319
138. Imazio M, Brucato A, Ferrazzi P, et al; COPPS-2 Investigators. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014;312:1016-1023. doi: 10.1001/jama.2014.11026
139. Bangert A, Andrassy M, Müller AM, Bockstahler M, Fischer A, Volz CH, Leib C, Göser S, Korkmaz-Icöz S, Zittrich S, Jungmann A, Lasitschka F, Pfitzer G, Müller OJ, Katus HA, Kaya Z. Critical role of RAGE and HMGB1 in inflammatory heart disease. Proc Natl Acad Sci USA. 2016;113:E155-E164. doi: 10.1073/pnas.1522288113
140. Björk P, Björk A, Vogl T, Stenström M, Liberg D, Olsson A, Roth J, Ivars F, Leanderson T. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol. 2009;7:e97. doi: 10.1371/journal.pbio.1000097
141. Brower V. Tasquinimod treatment for prostate cancer. Lancet Oncol. 2016;17:e322. doi: 10.1016/S1470-2045(16)30272-8
142. Muller I, Vogl T, Pappritz K, Miteva K, Savvatis K, Rohde D, Most P, Lassner D, Pieske B, Kuhl U, Van Linthout S, Tschope C. Pathogenic role of the damage-associated molecular patterns S100A8 and S100A9 in coxsackievirus b3-induced myocarditis. Circ Heart Fail. 2017;10:e004125.
143. Bhardwaj G, Dörr M, Sappa PK, Ameling S, Dhople V, Steil L, Klingel K, Empen K, Beug D, Völker U, Felix SB, Hammer E. Endomyocardial proteomic signature corresponding to the response of patients with dilated cardiomyopathy to immunoadsorption therapy. J Proteomics. 2017;150:121-129. doi: 10.1016/j.jprot.2016.09.001
144. Cao Y, Xu W, Xiong S. Adoptive transfer of regulatory T cells protects against Coxsackievirus B3-induced cardiac fibrosis. PLoS One. 2013;8:e74955. doi: 10.1371/journal.pone.0074955
145. Shi Y, Fukuoka M, Li G, Liu Y, Chen M, Konviser M, Chen X, Opavsky MA, Liu PP. Regulatory T cells protect mice against coxsackievirusinduced myocarditis through the transforming growth factor beta-coxsackie-adenovirus receptor pathway. Circulation. 2010;121:2624-2634. doi: 10.1161/CIRCULATIONAHA.109.893248
146. Pappritz K, Savvatis K, Lindner D, Westermann D, Melzig MF, Schultheiss HP, Tschöpe C. Administration of regulatory T cells ameliorates myocardial inflammation in experimental myocarditis. Eur Heart J 2013;34:279.
147. Koch M, Savvatis K, Scheeler M, Dhayat S, Bonaventura K, Pohl T, Riad A, Bulfone-Paus S, Schultheiss HP, Tschöpe C. Immunosuppression with an interleukin-2 fusion protein leads to improved LV function in experimental ischemic cardiomyopathy. Int Immunopharmacol. 2010;10:207-212. doi: 10.1016/j.intimp.2009.11.001
148. Van Linthout S, Savvatis K, Miteva K, Peng J, Ringe J, Warstat K, Schmidt-Lucke C, Sittinger M, Schultheiss HP, Tschöpe C. Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis. Eur Heart J. 2011;32:2168-2178. doi: 10.1093/eurheartj/ehq467
149. Savvatis K, van Linthout S, Miteva K, Pappritz K, Westermann D, Schefold JC, Fusch G, Weithäuser A, Rauch U, Becher PM, Klingel K, Ringe J, Kurtz A, Schultheiss HP, Tschöpe C. Mesenchymal stromal cells but not cardiac fibroblasts exert beneficial systemic immunomodulatory effects in experimental myocarditis. PLoS One. 2012;7:e41047. doi: 10.1371/journal.pone.0041047
150. Miteva K, Van Linthout S, Volk HD, Tschöpe C. Immunomodulatory effects of mesenchymal stromal cells revisited in the context of inflammatory cardiomyopathy. Stem Cells Int. 2013;2013:353097. doi: 10.1155/2013/353097
151. Miteva K, Pappritz K, El-Shafeey M, Dong F, Ringe J, Tschöpe C, Van Linthout S. Mesenchymal stromal cells modulate monocytes trafficking in coxsackievirus b3-induced myocarditis. Stem Cells Transl Med. 2017;6:1249-1261. doi: 10.1002/sctm.16-0353
152. Miteva K, Pappritz K, Sosnowski M, El-Shafeey M, Müller I, Dong F, Savvatis K, Ringe J, Tschöpe C, Van Linthout S. Mesenchymal stromal cells inhibit NLRP3 inflammasome activation in a model of Coxsackievirus B3-induced inflammatory cardiomyopathy. Sci Rep. 2018;8:2820. doi: 10.1038/s41598-018-20686-6
153. Silva DN, de Freitas Souza BS, Azevedo CM, Vasconcelos JF, Carvalho RH, Soares MB, Dos Santos RR. Intramyocardial transplantation of cardiac mesenchymal stem cells reduces myocarditis in a model of chronic Chagas disease cardiomyopathy. Stem Cell Res Ther. 2014;5:81. doi: 10.1186/scrt470
154. Carmona MD, Cañadillas S, Romero M, Blanco A, Nogueras S, Herrera C. Intramyocardial bone marrow mononuclear cells versus bone marrow-derived and adipose mesenchymal cells in a rat model of dilated cardiomyopathy. Cytotherapy. 2017;19:947-961. doi: 10.1016/j.jcyt. 2017.05.006
155. Hare JM, DiFede DL, Rieger AC, et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM Trial. J Am Coll Cardiol. 2017;69:526-537. doi: 10.1016/j.jacc.2016.11.009
156. Miteva K, Haag M, Peng J, Savvatis K, Becher PM, Seifert M, Warstat K, Westermann D, Ringe J, Sittinger M, Schultheiss HP, Tschöpe C, Van Linthout S. Human cardiac-derived adherent proliferating cells reduce murine acute Coxsackievirus B3-induced myocarditis. PLoS One. 2011;6:e28513. doi: 10.1371/journal.pone.0028513
157. Leuschner F, Courties G, Dutta P, et al. Silencing of CCR2 in myocarditis. Eur Heart J. 2015;36:1478-1488. doi: 10.1093/eurheartj/ehu225
158. Sutterwala FS, Haasken S, Cassel SL. Mechanism of NLRP3 inflammasome activation. Ann N Y Acad Sci. 2014;1319:82-95. doi: 10.1111/nyas.12458
159. Tschope C, Muller I, Xia Y, et al. NOD2 (Nucleotide-Binding Oligomerization Domain 2) is a major pathogenic mediator of coxsackievirus b3-induced myocarditis. Circ Heart Fail. 2017;10:e003870.
160. Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;10:210-215. doi: 10.1038/nri2725
161. Toldo S, Kannan H, Bussani R, Anzini M, Sonnino C, Sinagra G, Merlo M, Mezzaroma E, De-Giorgio F, Silvestri F, Van Tassell BW, Baldi A, Abbate A. Formation of the inflammasome in acute myocarditis. Int J Cardiol. 2014;171:e119-e121. doi: 10.1016/j.ijcard.2013.12.137
162. Wang Y, Gao B, Xiong S. Involvement of NLRP3 inflammasome in CVB3-induced viral myocarditis. Am J Physiol Heart Circ Physiol. 2014;307:H1438-H1447. doi: 10.1152/ajpheart.00441.2014
163. Bracey NA, Beck PL, Muruve DA, Hirota SA, Guo J, Jabagi H, Wright JR Jr, Macdonald JA, Lees-Miller JP, Roach D, Semeniuk LM, Duff HJ. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β. Exp Physiol. 2013;98:462-472. doi: 10.1113/expphysiol.2012.068338
164. Kraft L, Erdenesukh T, Sauter M, Tschöpe C, Klingel K. Blocking the IL-1β signalling pathway prevents chronic viral myocarditis and cardiac remodeling. Basic Res Cardiol. 2019;114:11. doi: 10.1007/s00395-019-0719-0
165. Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos PN, Kremastinos DT. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation. 2008;117:2662-2669. doi: 10.1161/CIRCULATIONAHA.107.731877
166. Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R, Roach LM, Arena RA, Roberts CS, Varma A, Gelwix CC, Salloum FN, Hastillo A, Dinarello CA, Vetrovec GW; VCUART Investigators. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCUART] Pilot study). Am J Cardiol. 2010;105:1371.e1-1377.e1. doi: 10.1016/j.amjcard.2009.12.059
167. Van Tassell BW, Canada J, Carbone S, et al. Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). Circ Heart Fail2017;10:e004373.
168. Van Tassell BW, Trankle CR, Canada JM, et al. IL-1 blockade in patients with heart failure with preserved ejection fraction. Circ Heart Fail. 2018;11:e005036. doi: 10.1161/CIRCHEARTFAILURE.118.005036
169. Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the airtrip randomized clinical trial. JAMA. 2016;316:1906-1912. doi: 10.1001/jama.2016.15826
170. Van Tassell BW, Lipinski MJ, Appleton D, et al. Rationale and design of the virginia commonwealth university-anakinra remodeling trial-3 (VCU-ART3): a randomized, placebo-controlled, double-blinded, multicenter study. Clin Cardiol. 2018;41:1004-1008. doi: 10.1002/clc.22988
171. http://www.clinicaltrials.gov. Unique identifier: NCT03018834.
172. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237-241. doi: 10.1038/nature04516
173. Leung YY, Yao Hui LL, Kraus VB. Colchicine-Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45:341-350. doi: 10.1016/j.semarthrit.2015.06.013
174. Adler Y, Charron P, Imazio M, et al; ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36:2921-2964. doi: 10.1093/eurheartj/ehv318
175. Van Linthout S, pappritz K, Lin J, Sosnowski M, El-Shafeey M, Tschöpe C. Colchicine reduces NLRP3 inflammasome activity in murine Coxsackievirus B3-induced myocarditis. Eur Heart J. 2018;39:P2845.
176. Gultekin N, Kucukates E. Microtubule inhibition therapy by colchicine in severe myocarditis especially caused by Epstein-Barr and cytomegalovirus co-infection during a two-year period: a novel therapeutic approach. J Pak Med Assoc. 2014;64:1420-1423.
177. Smilde BJ, Woudstra L, Fong Hing G, Wouters D, Zeerleder S, Murk JL, van Ham M, Heymans S, Juffermans LJ, van Rossum AC, Niessen HW, Krijnen PA, Emmens RW. Colchicine aggravates coxsackievirus B3 infection in mice. Int J Cardiol. 2016;216:58-65. doi: 10.1016/j.ijcard.2016.04.144
178. Raucci A, Di Maggio S, Scavello F, D'Ambrosio A, Bianchi ME, Capogrossi MC. The Janus face of HMGB1 in heart disease: a necessary update. Cell Mol Life Sci. 2019;76:211-229. doi: 10.1007/s00018-018-2930-9
179. Musumeci D, Roviello GN, Montesarchio D. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol Ther. 2014;141:347-357. doi: 10.1016/j. pharmthera.2013.11.001
180. Vogl T, Ludwig S, Goebeler M, Strey A, Thorey IS, Reichelt R, Foell D, Gerke V, Manitz MP, Nacken W, Werner S, Sorg C, Roth J. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood. 2004;104:4260-4268. doi: 10.1182/blood-2004-02-0446
181. Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86:557-566. doi: 10.1189/jlb.1008647
182. Van Crombruggen K, Vogl T, Pérez-Novo C, Holtappels G, Bachert C. Differential release and deposition of S100A8/A9 proteins in inflamed upper airway tissue. Eur Respir J. 2016;47:264-274. doi: 10.1183/13993003.00159-2015
183. Cotoi OS, Dunér P, Ko N, Hedblad B, Nilsson J, Björkbacka H, Schiopu A. Plasma S100A8/A9 correlates with blood neutrophil counts, traditional risk factors, and cardiovascular disease in middle-aged healthy individuals. Arterioscler Thromb Vasc Biol. 2014;34:202-210. doi: 10.1161/ATVBAHA.113.302432
184. Müller F, Frøland SS, Aukrust P, Fagerhol MK. Elevated serum calprotectin levels in HIV-infected patients: the calprotectin response during ZDV treatment is associated with clinical events. J Acquir Immune Defic Syndr. 1994;7:931-939.
185. Müller I, Pappritz K, Savvatis K, Puhl K, Dong F, El-Shafeey M, Hamdani N, Hamann I, Noutsias M, Infante-Duarte C, Linke WA, Van Linthout S, Tschöpe C. CX3CR1 knockout aggravates Coxsackievirus B3-induced myocarditis. PLoS One. 2017;12:e0182643. doi: 10.1371/journal.pone.0182643
186. Simard JC, Cesaro A, Chapeton-Montes J, Tardif M, Antoine F, Girard D, Tessier PA. S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent activation of NF-κB(1.). PLoS One. 2013;8:e72138. doi: 10.1371/journal.pone.0072138
187. Müller I, Kühl U, Vogl T, Pieske B, Tschöpe C, Van Linthout S. S100A8/S100A9 alarmin as a potential biomarker in patients with active myocarditis. Clin Res Cardiol 2018;107:V1163.
188. Marchant DJ, McManus BM. Regulating viral myocarditis: allografted regulatory T cells decrease immune infiltration and viral load. Circulation. 2010;121:2609-2611. doi: 10.1161/CIRCULATIONAHA.110.960054
189. Tang H, Zhong Y, Zhu Y, Zhao F, Cui X, Wang Z. Low responder T cell susceptibility to the suppressive function of regulatory T cells in patients with dilated cardiomyopathy. Heart. 2010;96:765-771. doi: 10.1136/hrt.2009.184945
190. Chen P, Baldeviano GC, Ligons DL, Talor MV, Barin JG, Rose NR, Cihakova D. Susceptibility to autoimmune myocarditis is associated with intrinsic differences in CD4(+) T cells. Clin Exp Immunol. 2012;169:79-88. doi: 10.1111/j.1365-2249.2012.04598.x
191. Li J, Wang L, Wang S, Zhu H, Ye P, Xie A, Shen B, Liu C, Guo C, Fu Q, Zhang K, Xia J. The Treg/Th17 imbalance in patients with idiopathic dilated cardiomyopathy. Scand J Immunol. 2010;71:298-303. doi: 10.1111/j.1365-3083.2010.02374.x
192. Valaperti A, Marty RR, Kania G, Germano D, Mauermann N, Dirnhofer S, Leimenstoll B, Blyszczuk P, Dong C, Mueller C, Hunziker L, Eriksson U. CD11b+ monocytes abrogate Th17 CD4+ T cell-mediated experimental autoimmune myocarditis. J Immunol. 2008;180:2686-2695.
193. Rangachari M, Mauermann N, Marty RR, Dirnhofer S, Kurrer MO, Komnenovic V, Penninger JM, Eriksson U. T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med. 2006;203:2009-2019. doi: 10.1084/jem.20052222
194. Wu L, Ong S, Talor MV, Barin JG, Baldeviano GC, Kass DA, Bedja D, Zhang H, Sheikh A, Margolick JB, Iwakura Y, Rose NR, Ciháková D. Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy. J Exp Med. 2014;211:1449-1464. doi: 10.1084/jem.20132126
195. Chen G, Bracamonte-Baran W, Diny NL, Hou X, Talor MV, Fu K, Liu Y, Davogustto G, Vasquez H, Taegtmeyer H, Frazier OH, Waisman A, Conway SJ, Wan F, Ciháková D. Sca-1+ cardiac fibroblasts promote development of heart failure. Eur J Immunol. 2018;48:1522-1538. doi: 10.1002/eji.201847583
196. Eisenstein EM, Williams CB. The T(reg)/Th17 cell balance: a new paradigm for autoimmunity. Pediatr Res. 2009;65(5 pt 2):26R-31R. doi: 10.1203/PDR.0b013e31819e76c7
197. Abou-El-Enein M, Volk HD, Reinke P. Clinical Development of cell therapies: setting the stage for academic success. Clin Pharmacol Ther. 2017;101:35-38.
198. Fan MY, Low JS, Tanimine N, Finn KK, Priyadharshini B, Germana SK, Kaech SM, Turka LA. Differential Roles of IL-2 signaling in developing versus mature tregs. Cell Rep. 2018;25:1204.e4-1213.e4. doi: 10.1016/j.celrep.2018.10.002
199. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo JL, Kohler RH, Chudnovskiy A, Waterman P, Aikawa E, Mempel TR, Libby P, Weissleder R, Pittet MJ. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009;325:612-616. doi: 10.1126/science.1175202
200. Ismahil MA, Hamid T, Bansal SS, Patel B, Kingery JR, Prabhu SD. Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis. Circ Res. 2014;114:266-282. doi: 10.1161/CIRCRESAHA.113.301720
201. Prather WR, Toren A, Meiron M, Ofir R, Tschope C, Horwitz EM. The role of placental-derived adherent stromal cell (PLX-PAD) in the treatment of critical limb ischemia. Cytotherapy. 2009;11:427-434. doi: 10.1080/14653240902849762
202. Consentius C, Akyüz L, Schmidt-Lucke JA, Tschöpe C, Pinzur L, Ofir R, Reinke P, Volk HD, Juelke K. Mesenchymal stromal cells prevent allostimulation In Vivo and control checkpoints of th1 priming: migration of human DC to lymph nodes and NK cell activation. Stem Cells. 2015;33:3087-3099. doi: 10.1002/stem.2104
203. Winkler T, Perka C, von Roth P, Agres AN, Plage H, Preininger B, Pumberger M, Geissler S, Hagai EL, Ofir R, Pinzur L, Eyal E, Stoltenburg-Didinger G, Meisel C, Consentius C, Streitz M, Reinke P, Duda GN, Volk HD. Immunomodulatory placental-expanded, mesenchymal stromal cells improve muscle function following hip arthroplasty. J Cachexia Sarcopenia Muscle. 2018;9:880-897. doi: 10.1002/jcsm.12316
204. Roy R, Brodarac A, Kukucka M, Kurtz A, Becher PM, Jülke K, Choi YH, Pinzur L, Chajut A, Tschöpe C, Stamm C. Cardioprotection by placentaderived stromal cells in a murine myocardial infarction model. J Surg Res. 2013;185:70-83. doi: 10.1016/j.jss.2013.05.084
205. Van Linthout S, Hamdani N, Miteva K, Koschel A, Müller I, Pinzur L, Aberman Z, Pappritz K, Linke WA, Tschöpe C. Placenta-derived adherent stromal cells improve diabetes mellitus-associated left ventricular diastolic performance. Stem Cells Transl Med. 2017;6:2135-2145. doi: 10.1002/sctm.17-0130
206. Nakano Y, Matoba T, Tokutome M, Funamoto D, Katsuki S, Ikeda G, Nagaoka K, Ishikita A, Nakano K, Koga J, Sunagawa K, Egashira K. Nanoparticle-mediated delivery of irbesartan induces cardioprotection from myocardial ischemia-reperfusion injury by antagonizing monocyte-mediated inflammation. Sci Rep. 2016;6:29601. doi: 10.1038/srep29601
207. Okuda K, Fu HY, Matsuzaki T, et al. Targeted therapy for acute autoimmune myocarditis with nano-sized liposomal FK506 in rats. PLoS One. 2016;11:e0160944. doi: 10.1371/journal.pone.0160944
208. Jia C, Chen H, Wei M, Chen X, Zhang Y, Cao L, Yuan P, Wang F, Yang G, Ma J. Gold nanoparticle-based miR155 antagonist macrophage delivery restores the cardiac function in ovariectomized diabetic mouse model. Int J Nanomedicine. 2017;12:4963-4979. doi: 10.2147/IJN.S138400
209. Lozano O, Torres-Quintanilla A, García-Rivas G. Nanomedicine for the cardiac myocyte: where are we? J Control Release. 2018;271:149-165. doi: 10.1016/j.jconrel.2017.12.018
210. Paul A, Hasan A, Kindi HA, Gaharwar AK, Rao VT, Nikkhah M, Shin SR, Krafft D, Dokmeci MR, Shum-Tim D, Khademhosseini A. Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair. ACS Nano. 2014;8:8050-8062. doi: 10.1021/nn5020787
211. Ruiz-Esparza GU, Segura-Ibarra V, Cordero-Reyes AM, et al. A specifically designed nanoconstruct associates, internalizes, traffics in cardiovascular cells, and accumulates in failing myocardium: a new strategy for heart failure diagnostics and therapeutics. Eur J Heart Fail. 2016;18:169-178. doi: 10.1002/ejhf.463
212. Meyer IS, Goetzke CC, Kespohl M, Sauter M, Heuser A, Eckstein V, Vornlocher HP, Anderson DG, Haas J, Meder B, Katus HA, Klingel K, Beling A, Leuschner F. Silencing the CSF-1 axis using nanoparticle encapsulated siRNA mitigates viral and autoimmune myocarditis. Front Immunol. 2018;9:2303. doi: 10.3389/fimmu.2018.02303
213. Van Linthout S, Tschöpe C. Lost in markers? Time for phenomics and phenomapping in dilated cardiomyopathy. Eur J Heart Fail. 2017;19:499-501. doi: 10.1002/ejhf.744
214. Antman EM, Loscalzo J. Precision medicine in cardiology. Nat Rev Cardiol. 2016;13:591-602. doi: 10.1038/nrcardio.2016.101
215. Noutsias M, Tschöpe C. Giant cell myocarditis: still a conundrum. The need for a worldwide registry. Eur J Heart Fail. 2016;18:1459-1461. doi: 10.1002/ejhf.648